Introduction {#sec1-1}
============

The elucidation of the human genome has revitalized the interest in using proteins or pieces of proteins (peptides) for the treatment of presently incurable diseases.[1](#bib1){ref-type="ref"}, [2](#bib2){ref-type="ref"}, [3](#bib3){ref-type="ref"} Human diseases for which the peptide‐based drug therapies are applied include osteoporosis (calcitonin), diabetes (insulin), prostate cancer and endometriosis (gonadotropin‐releasing hormone), acromegaly and ulcers (somatostatin), as well as hypothyroidism (thyrotropin‐releasing hormone, TRH).[1](#bib1){ref-type="ref"}, [4](#bib4){ref-type="ref"} The brain, as a major control center, is an important target for many pharmaceutical drugs, such as opioid peptide analogues designed for the treatment of pain, neuropeptides and growth peptides for the treatment of neurological disorders. One of the recently most remarkable examples of peptide drugs is the HIV fusion inhibitor T‐20, which is a 36‐peptide derived from the structure of gp41 and practically used in clinical treatment for AIDS patients.[5](#bib5){ref-type="ref"} HIV entry inhibitors[6](#bib6){ref-type="ref"} are the first antiretroviral drugs in widespread clinical evaluation to target HIV replication at sites other than reverse transcriptase or protease as focused previously (see, e.g., Refs.[7](#bib7){ref-type="ref"}, [8](#bib8){ref-type="ref"}, [9](#bib9){ref-type="ref"}, [10](#bib10){ref-type="ref"}, [11](#bib11){ref-type="ref"}, [12](#bib12){ref-type="ref"}, [13](#bib13){ref-type="ref"}, [14](#bib14){ref-type="ref"}). The HIV fusion inhibitors have received the fast‐track designation by the United States Food and Drug Administration because of the resistance of HIV to the drugs targeting on reverse transcriptase and protease. The successful implication of diverse peptides with special physiological activity in medicinal treatment has also increased the interest in exploiting peptides, peptide analogues, and peptide mimetics as therapeutic drugs.[15](#bib15){ref-type="ref"}, [16](#bib16){ref-type="ref"}, [17](#bib17){ref-type="ref"}, [18](#bib18){ref-type="ref"}, [19](#bib19){ref-type="ref"}, [20](#bib20){ref-type="ref"}

Peptide reagent design may be one of the most challenging research topics in life science owing to the extremely large amount of possible arrangements. For example, for an octapeptide sample, the number of possible sequence arrangements[13](#bib13){ref-type="ref"}, [21](#bib21){ref-type="ref"} are 20^8^ = 2.56 × 10^10^; for designing a peptide regent of 36 amino acids, the number of possible amino acid sequence arrangement would be 20^36^ = 6.87 × 10^46^. This is an astronomical number! Therefore, it is vitally important to develop a computational method to guide us for efficiently designing peptide reagents. The present study was initiated in an attempt to develop a rational peptide reagent design method on the basis of the physical and chemical properties of amino acids, particularly their heuristic molecular lipophilicity potential (HMLP) parameters.[22](#bib22){ref-type="ref"}, [23](#bib23){ref-type="ref"}, [24](#bib24){ref-type="ref"} Unlike the purely statistical techniques in drug design that only pursue the statistical results without physical and chemical rationale, the HMLP approach has a solid theoretical foundation. Moreover, the prediction equations not only can indicate the bioactivity of a query peptide reagent but also can reveal the physical and chemical features for each of the subsites along the peptide sequence.

Theory and Method {#sec1-2}
=================

The calculation of interaction free energy between two peptides, or between a peptide and a protein, is a fundamental problem in protein science and medicinal chemistry. In this study, the peptide--protein interaction is simplified as the interaction between a peptide reagent P~*i*~ and a target peptide P~0~, which is a segment of a protein receptor, or a set of amino acid residues at its active sites. The main idea of peptide--protein interaction is schematically illustrated in Figure [1](#fig1){ref-type="fig"}, where panel A shows the peptide fusion inhibitors interacting with a part of the HIV‐1 gp41 envelope glycoprotein, and panel B shows the amino acid residues of peptide substrates interacting with the active sites of SARS coronavirus main protease.

![Protein and peptide targets of peptide reagents. (A) C peptides derived from the C‐region of gp41, such as C34, bind to the N‐region in its trimeric coiled‐coil state; the proteins N~CCG~‐gp41 and 5‐helix, which expose either the complete or a portion of the N‐region trimeric coiled‐coil in a stable form, bind to the C‐region. N peptides may target a vulnerable C‐helix region of gp41. Alternatively, the N peptides could intercalate with the N helices of gp41 to form a heterotrimeric coiled‐coil and interfere with the coiled‐coil formation of gp41. (B) Interaction between peptide substrate and SARS coronavirus main protease. The amino acid residues of peptide substrates interact with the active sites of SARS coronavirus main protease. Figure 1B was adapted from Figure [2](#fig2){ref-type="fig"} of Chou (Ref.[13](#bib13){ref-type="ref"}, with permission from Academic Press). \[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.\]](JCC-28-2043-g006){#fig1}

The binding free energy Δ*G* $\,_{\text{0}}^{\textit{i}}$ between peptide P~*i*~ and its target peptide P~0~ is considered as the summation of interactions from all residue pairs of two peptides at the corresponding sequence positions; i.e., where Δ*g* ~*i*,*α*~ is the interaction free energy of residue pair at position *α* of peptide P~i~ and target peptide P~0~, and *M* is the total number of residue pairs involved. The binding free energy Δ*g* ~*i*,*α*~ from different residue pairs may have different weights to the total free energy Δ*G* $\,_{\text{0}}^{\textit{i}}$ due to their different microenvironments and different roles in bioactivity. We use a set of sensitive coefficients {*b* ~*α*~} to describe their microenvironments of residues. The binding free energy Δ*g* ~*i*,*α*~ of residue pair *α* is described by a series of physical and chemical properties of amino acids. In this study we use the heuristic molecular lipophilicity potential (HMLP) parameters of amino acids through the following linear free energy equation[22](#bib22){ref-type="ref"}, [23](#bib23){ref-type="ref"}, [24](#bib24){ref-type="ref"}: where *R* ~0,*i,α*~ is the distance between peptide P~*i*~ and peptide P~0~ at residue position *α*, and *γ* is an exponent. In eq. [(2)](#eqn2){ref-type="disp-formula"}, *H* ~*i*,*α*~ and *L* ~*i*,α~ are respectively the hydrophilic parameter and lipophilic parameter of residue *α* in peptide P~*i*~; ![](JCC-28-2043-e021.jpg "equation image") and ![](JCC-28-2043-e049.jpg "equation image") are the surface areas of residue *α* with hydrophilic potential and lipophilic potential, respectively. Similarly, *H* ~0,*α*~, *L* ~0,*α*~, ![](JCC-28-2043-e048.jpg "equation image"), and ![](JCC-28-2043-e013.jpg "equation image") are the HMLP parameters of target peptide P~0~. The HMLP parameters of amino acids were derived from the quantum chemical electrostatic potential with the ability to reflect the hydrophilic and lipophilic interactions of amino acid residues.[25](#bib25){ref-type="ref"}, [26](#bib26){ref-type="ref"}, [27](#bib27){ref-type="ref"} The first term in eq. [(2)](#eqn2){ref-type="disp-formula"} describes the hydrophilic interactions, including the hydrogen bond interaction, ionic interaction, and dipole interaction; the second term describes the lipophilic interaction between amino acid residues; while the third and fourth terms describe the free energies from the solvation and dissolvation of amino acid residues, respectively. In eq. [(2)](#eqn2){ref-type="disp-formula"} we can add other terms that can affect the interaction or recognition between peptide ligand and protein receptor.

Actually, peptide P~0~ is a virtual target peptide, and we do not need to know its real chemical structure. If the HMLP parameters *H* ~0,*α*~, *L* ~0,*α*~, ![](JCC-28-2043-e033.jpg "equation image"), and ![](JCC-28-2043-e016.jpg "equation image") of the virtual target peptide P~0~ and the distance *R* ~0,*i,α*~ are assumed to be constants, eq. [(2)](#eqn2){ref-type="disp-formula"} will be reduced to a linear equation of the HMLP parameters of peptide P~*i*~; i.e., where *v* ~*i,α,l*~ denotes the *l*‐th HMLP parameter of peptide P~*i*~ of amino acid residue at peptide position *α*. The role of the coefficients {*a* ~*l*~} is the same as in traditional 2D‐QSAR. Inserting the Δ*g* ~*i*,*α*~ of eq. [(3)](#eqn3){ref-type="disp-formula"} into eq. [(1)](#eqn1){ref-type="disp-formula"} and transferring the binding free energy Δ*G* $\,_{\text{0}}^{\textit{i}}$ to bioactivity *pk* ~*i*~ = −log*k* ~*i*~ = Δ*G* $\,_{\text{0}}^{\textit{i}}$ of peptide P~*i*~, we obtain the following simultaneous linear equations, where *N* is the number of peptide samples, *M* is the number of amino acid residues in the peptides, and *L* is the number of physicochemical parameters of amino acid residues. In a training set of peptide reagents, the physicochemical parameters form a three‐dimensional data matrix, *V* ~*N*×*M*×*L*~, as shown in Figure [2](#fig2){ref-type="fig"}.

![Schemetic illustration of the three‐dimensional data matrix and iterative double least square (IDLS) solution. *N* is the number of peptide samples, *M* is the number of amino acid residues in peptide, and *L* is the number of physicochemical parameters of amino acid residues.](JCC-28-2043-g001){#fig2}

Although the transformation from eq. [(1)](#eqn1){ref-type="disp-formula"} to eq. [(4)](#eqn4){ref-type="disp-formula"} is not a rigorous theoretical derivation, it can be used to explain the physical implication of the linear free energy equation and the functions of HMLP parameters and some theoretical considerations in our model. Like all other QSAR approaches, the linear free energy equation is not unique. However, we can refine the binding free energy by utilizing other linear free energy equations and including more parameters.

In eq. [(4)](#eqn4){ref-type="disp-formula"} there are two sets of coefficients: {*a* ~*l*~} are sensitive coefficients of the physicochemical parameters, and {*b* ~*α*~} are the sensitive coefficients of amino acid residue positions in peptides. An iterative double least square (IDLS) technique was developed to determine the values of the coefficient sets {*a* ~*l*~} and {*b* ~*α*~} alternately by solving the three‐dimensional simultaneous linear equations. By using a set of initial values of coefficients {*a* $\,_{\textit{l}}^{\text{(0)}}$}, the three‐dimensional data matrix *V* ~*N*×*M*×*L*~ is reduced to a two‐dimensional data matrix *D* $\,_{\text{(1)}}^{\textit{N}\text{×}\textit{M}}$ with the elements given byThus, the set of three‐dimensional simultaneous linear equations \[eq. [(4)](#eqn4){ref-type="disp-formula"}\] is reduced to a set of two‐dimensional equations, i.e.,The above equation set can be solved by using the least square approach, yielding the first solutions of the sensitive coefficients ![](JCC-28-2043-e006.jpg "equation image"). Then the values of ![](JCC-28-2043-e001.jpg "equation image") are used to reduce the three‐dimensional data matrix *V* ~*N*×*M*×*L*~ to a two‐dimensional data matrix *T* $\,_{\text{(1)}}^{\textit{N}\text{×}\textit{L}}$ with the elements given by Similarly, the set of three‐dimensional simultaneous linear equations \[eq. [(4)](#eqn4){ref-type="disp-formula"}\] is reduced to a set of two‐dimensional equations by eq. [(7)](#eqn7){ref-type="disp-formula"}, as given byThe above equation can be solved by using the least square approach, leading to the solution of sensitive coefficients {*a* $\,_{\textit{l}}^{\text{(1)}}$}. Then the values of {*a* $\,_{\textit{l}}^{\text{(1)}}$} are used for the new solutions of the sensitive coefficients {*b* $\,_{\text{α}}^{\text{(2)}}$} of amino acid residue positions. The above procedure is performed iteratively for *n* steps, i.e., until reaching the converged solutions as denoted by {*a* $\,_{\textit{l}}^{\text{(}\textit{n}\text{)}}$} and {*b* $\,_{\textit{α}}^{\text{(}\textit{n}\text{)}}$}. Now, the values of {*a* $\,_{\textit{l}}^{\text{(}\textit{n}\text{)}}$} and {*b* $\,_{\textit{α}}^{\text{(}\textit{n}\text{)}}$} can be used to predict the bioactivities *pk* $\,_{\textit{i}}^{\text{(pred)}}$ of the *i*‐th peptide reagent through the following equation: where the term *b* $\,_{\textit{α}}^{\text{(}\textit{n}\text{)}}$Δ*g* ~*i,α*~ is the contribution of amino acid *α* of the *i*‐th peptide reagent to the bioactivity. The convergence criterion for the iterative procedure is given by the following equation where *Q* ^(*n*)^ represents difference between the square root of the summation of squared differences between experimental bioactivities and the predicted bioactivities in the *n*th step, and *Q* ^(*n*+1)^ that in the (*n* + 1)th step.

Calculations and Results {#sec1-3}
========================

In this section two calculation examples are used to prove the predictive power of AABPD. The HMLP parameters of the 20 natural amino acid residues are taken from our previous work[22](#bib22){ref-type="ref"} and listed in Table[1](#tbl1){ref-type="table"} with the secondary structural potency indices. One of the merits of the HMLP approach is that it can provide a lipophilic index and a hydrophilic index for every amino acid side chain, describing its lipophilic moiety and hydrophilic moiety, respectively. In the first example the 22 octapeptides in training set is taken from Ref.[28](#bib28){ref-type="ref"}, which was originally used in the substrate specificity study for the SARS coronavirus 3C‐like proteinase.[29](#bib29){ref-type="ref"}, [30](#bib30){ref-type="ref"} In Table[2](#tbl2){ref-type="table"}, the notation ↓ indicates the cleavage site in octapeptides. From ↓ to left side, the amino acid residues are numbered as R1, R2, R3, R4, and R5; from ↓ to right side, the amino acid residues are numbered as R1′, R2′, and R3′. The first octapeptide S12 (SAVLQ↓SGF‐CONH2) is the parent of other octapeptides in the training set. It is a naturally cleavable peptide of 3C‐like proteinase, derived from polyprotein pp1ab of SARS coronavirus, covering the first cleavage site of pp1ab.[31](#bib31){ref-type="ref"}, [32](#bib32){ref-type="ref"}, [33](#bib33){ref-type="ref"}, [34](#bib34){ref-type="ref"} Other octapeptides are mutated from octapeptide S12, in which one or more residues are replaced. In Table [2](#tbl2){ref-type="table"} the mutated residues are indicated with bold letters. The names of octapeptides used in this study are the same as in Ref.[28](#bib28){ref-type="ref"}.

###### 

HMLP Parameters[a](#fn1){ref-type="fn"} and Secondary Structural Potencies of 20 Amino Acids Side Chains.

  A.A.      *S* ^L^ (Å^2^)   *S* ^H^ (Å^2^)   *L*      *H*       ^*b*^ *P* ~*α*~   ^*b*^ *P* ~*β*~   ^*b*^ *P* ~*c*~
  --------- ---------------- ---------------- -------- --------- ----------------- ----------------- -----------------
  Leu (L)   84.5476          0.0000           1.2906   0.0000    1.21              1.30              0.68
  Ile (I)   88.6055          0.0000           1.1046   0.0000    1.08              1.60              0.66
  Val (V)   77.8108          0.0000           0.5324   0.0000    1.06              1.70              0.62
  Phe (F)   105.7054         11.2472          0.4412   −0.1195   1.13              1.38              0.71
  Met (M)   70.3631          23.2299          1.0768   −0.3068   1.45              1.05              0.58
  Trp (W)   133.6980         14.8820          0.8364   −0.4310   1.08              1.37              0.75
  Ala (A)   34.7760          0.0000           0.1744   0.0000    1.42              0.83              0.70
  Cys (C)   23.5563          30.4540          0.2479   −0.2402   0.70              1.19              1.18
  Gly (G)   3.7616           0.0000           0.0208   0.0000    0.57              0.75              1.50
  Tyr (Y)   80.9646          42.7160          0.4534   −0.5896   0.69              1.47              1.06
  Thr (T)   46.7285          16.0490          1.4265   −0.4369   0.83              1.19              1.07
  Ser (S)   26.0681          15.9613          0.2346   −0.6040   0.77              0.75              1.32
  His (H)   82.1701          13.8631          0.8124   −0.7766   1.00              0.87              1.06
  Gln (Q)   70.0876          17.8662          1.0036   −0.7211   1.11              1.10              0.86
  Lys (K)   97.7144          8.0786           1.4600   −0.6229   1.16              0.74              0.98
  Asn (N)   50.5075          17.7804          0.6396   −0.7211   0.67              0.89              1.35
  Glu (E)   57.1582          25.5726          1.0315   −0.9298   1.51              0.37              0.84
  Asp (D)   37.4173          25.2736          0.6058   −0.9298   1.01              0.54              1.20
  Arg (R)   90.8008          35.3095          1.2424   −1.4797   0.98              0.93              1.04
  Pro (P)   69.2297          0.0000           0.3226   0.0000    0.57              0.55              1.59

Notations used: *S* ^*L*^, surface area of side chain with lipophilic potential; S^*H*^, surface area of side chain with hydrophilic potential; *L*, lipophilic index of side chains; *H*, hydrophilic index of side chains; *P* ~α~, α potency index; *P* ~β~, β potency index; *P* ~c~, coil potency index.
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###### 

Experimental and Predicted Peptide Substrate Cleavage Activities of SARS Coronavirus 3C‐like Proteinase.

  Name[a](#fn2){ref-type="fn"}   Sequence[b](#fn3){ref-type="fn"}   (*K* ~cat~/*K* ~m~)~rel~ [a](#fn2){ref-type="fn"}   log(*K* ~cat~/*K* ~m~)~expt~ [a](#fn2){ref-type="fn"}   log(*K* ~cat~/*K* ~m~)~calc~ [c](#fn4){ref-type="fn"}   log(*K* ~cat~/*K* ~m~)~pred~ [d](#fn5){ref-type="fn"}
  ------------------------------ ---------------------------------- --------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  S12                            SAVLQ↓SGF                          1.0000                                              0.0000                                                  −0.0338                                                 −0.0396
  P5L                            **L**AVLQ↓SGF                      3.9000                                              1.3610                                                  1.7060                                                  1.9394
  P5T                            **T**AVLQ↓SGF                      3.6600                                              1.2975                                                  1.3252                                                  1.3306
  P5V                            **V**AVLQ↓SGF                      3.5900                                              1.2782                                                  1.0332                                                  0.9280
  P5A                            **A**AVLQ↓SGF                      3.3300                                              1.2030                                                  0.6025                                                  0.3333
  P4L                            S**L**VLQ↓SGF                      0.1500                                              −1.8971                                                 −0.8152                                                 0.4788
  P4T                            S**T**VLQ↓SGF                      1.4700                                              0.3853                                                  −0.5455                                                 −0.9877
  P4V                            S**V**VLQ↓SGF                      2.4400                                              0.8920                                                  −0.3388                                                 −0.5486
  P3L                            SA**L**LQ↓SGF                      0.8700                                              −0.1393                                                 0.5149                                                  1.0315
  P3T                            SA**T**LQ↓SGF                      1.1900                                              0.1740                                                  0.2043                                                  0.2272
  P3A                            SA**A**LQ↓SGF                      0.1900                                              −1.6607                                                 −0.3850                                                 0.3295
  P3K                            SA**K**LQ↓SGF                      2.6800                                              0.9858                                                  −0.0289                                                 0.1694
  P1′A                           SAVLQ↓**A**GF                      2.0400                                              0.7130                                                  0.4130                                                  0.1084
  P1′G                           SAVLQ↓**G**GF                      0.8300                                              −0.1863                                                 0.2582                                                  Outlier
  P2M                            SAV**M**Q↓SGF                      0.2080                                              −1.5702                                                 −1.4607                                                 −1.3500
  P2F                            SAV**F**Q↓SGF                      0.0460                                              −3.0791                                                 −3.5378                                                 −4.5758
  P2V                            SAV**V**Q↓SGF                      0.0056                                              −5.1850                                                 −3.6989                                                 −2.9612
  P2A                            SAV**A**Q↓SGF                      0.0046                                              −5.3817                                                 −6.0456                                                 −5.5328
  S21                            **TV**VLQ↓SGF                      3.9800                                              1.3813                                                  1.0201                                                  0.9197
  S22                            **TVT**LQ↓SGF                      2.6200                                              0.9632                                                  1.2582                                                  1.4161
  S23                            **VVT**LQ↓SGF                      2.4300                                              0.8879                                                  0.9663                                                  0.9465
  S24                            **TVK**LQ↓AGF                      4.3100                                              1.4609                                                  1.4717                                                  1.5935

The names of peptides are taken from Ref.[28](#bib28){ref-type="ref"}. S12 is the parent peptide in the training set. All other peptides are mutated from it.

The notation ↓ indicates the cleavage site of SARS coronavirus 3C‐like proteinase.[13](#bib13){ref-type="ref"}

Calculated bioactivities of 22 octapeptides after 10 iterative calculations.

Predicted bioactivities of 21 octapeptides in Jackknife test.
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The iterative double least square (IDLS) technique described in the second Section is used in the peptide substrate specificity study for the SARS coronavirus 3C‐like proteinase based on the experimental data listed in Table [2](#tbl2){ref-type="table"}. The initial values of sensitive coefficients of physicochemical parameters {*a* $\,_{\textit{l}}^{\text{(0)}}$} are assigned to be 1.0. In the first calculation only four HMLP parameters are used, which yields the correlation coefficient *R* = 0.9375 and average predictive residue *Q* = ±0.4804. *Q* is the average square root of the summation of squared differences between predicted bioactivities and experimental bioactivities. Its definition can be found in eq. [(10)](#eqn10){ref-type="disp-formula"}. In the second calculation total of 7 parameters are used, which gives better results than the first calculation (*R* = 0.9705 and *Q* = ±0.2305). The other three parameters are the secondary structural potency indices of amino acid residues. The curves of correlation coefficients *R* is shown in Figure [3](#fig3){ref-type="fig"}, where *R* ~*a*~ is for the iterated coefficients {*a* $\,_{\textit{l}}^{\text{(n)}}$} and *R* ~*b*~ is for the iterated coefficients {*b* $\,_{\text{α}}^{\text{(n)}}$}. The average residue *Q* between the predicted bioactivities and the experimental bioactivities of octapeptides are shown in Figure [4](#fig4){ref-type="fig"}, where *Q* ~*a*~ is for {*a* $\,_{\textit{l}}^{\text{(n)}}$} and *Q* ~*b*~ is for {*b* $\,_{\text{α}}^{\text{(n)}}$}. It has been observed that, after 5--6 iterations, the iterative result is converged smoothly. The converged sensitive coefficient sets {*a* $\,_{\textit{l}}^{\text{(n)}}$} and {*b* $\,_{\text{α}}^{\text{(n)}}$}, as well as the corresponding *R* and *Q* for the octapeptides in the training dataset are given in Table [3](#tbl3){ref-type="table"}.

![The correlation coefficients between experimental and predicted bioactivities. *R* ~*a*~ is for {*a* $\,_{\textit{l}}^{\text{(}\textit{n}\text{)}}$} iteration and *R* ~*b*~ is for {*b* $\,_{\textit{j}}^{\text{(}\textit{n}\text{)}}$} iteration. \[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.\]](JCC-28-2043-g003){#fig3}

![The value of *Q* between predicted bioactivities and experimental bioactivities of octapeptides. *Q* ~*a*~ is for {*a* $\,_{\textit{l}}^{\text{(}\textit{n}\text{)}}$} iteration and *Q* ~*b*~ is for {*b* $\,_{\textit{j}}^{\text{(}\textit{n}\text{)}}$} iteration. The *Q* is the average square root of the summation of squared differences between predicted bioactivities and experimental bioactivities (cf. Eq. [10](#eqn10){ref-type="disp-formula"}). \[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.\]](JCC-28-2043-g005){#fig4}

###### 

The Converged Sensitive Coefficient Sets {*a* $\,_{\textit{l}}^{\text{(10)}}$}, {*b* $\,_{\textit{a}}^{\text{(10)}}$}, Correlation Coefficient *R*, and Average Residue *Q* of 22 Octapeptides in Training Calculation and in Jackknife Test.

  4 Parameters                 7 Parameters
  ---------------------------- ------------------------------
  *a* ~1~(*S* ^L^) = 0.16205   *a* ~1~(*S* ^L^) = 0.64288
  *a* ~2~(*S* ^H^) = 0.94055   *a* ~2~(*S* ^H^) = −0.60573
  *a* ~3~(*L*) = 45.11523      *a* ~3~(*L*) = 31.18381
  *a* ~4~(*H*) = 78.24573      *a* ~4~(*H*) = 7.90862
  --                           *a* ~5~(*P* ~α~) = 50.47151
  --                           *a* ~6~(*P* ~β~) = −26.15246
  --                           *a* ~7~(*P* ~c~) = −3.59095
  --                           --
  *R*                          *R*
  *Q*                          Q
  Jackknife Test               
  *R*                          --
  *Q*                          --
  *b* ~1~(R~5~) = 0.01925      *b* ~1~(R~5~) = 0.01875
  *b* ~2~(R~4~) = −0.01321     *b* ~2~(R~4~) = −0.04513
  *b* ~3~(R~3~) = 0.01682      *b* ~3~(R~3~) = 0.00510
  *b* ~4~(R~2~) = 0.10315      *b* ~4~(R~2~) = 0.11854
  *b* ~5~(R~1~) = −0.75093     *b* ~5~(R~1~) = −0.10948
  *b* ~6~(R′~1~) = 0.01418     *b* ~6~(R~1~′) = 0.00863
  *b* ~7~(R′~2~) = 26.69763    *b* ~7~(R~2~′) = −0.26087
  *b* ~8~(R′~3~) = −0.79655    *b* ~8~(R~3~′) = 0.05023
  0.9375                       0.9705
  ±0.4804                      ±0.2305
  0.8472                       --
  ±0.6375                      --
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The two sets of coefficients {*a* $\,_{\textit{l}}^{\text{(n)}}$} and {*b* $\,_{\text{α}}^{\text{(n)}}$} and eq. [(4)](#eqn4){ref-type="disp-formula"} can then be used for the bioactivity prediction of new peptide reagents. Jackknife test[35](#bib35){ref-type="ref"} is performed for evaluating the predictive power of AABPD approach. The predicted bioactivities of the 22 octapeptides obtained in the Jackknife test are listed in Table [2](#tbl2){ref-type="table"} with correlation coefficient *R* = 0.8472 and predictive residue *Q* = ±0.7375. In the Jackknife test we found that the octapeptide P1′G (SAVLQ↓GGF) is an outlier with an very high predicted bioactivity. This may be caused by the small training dataset with limited diversity. In octapeptide P1′G the residue serine (S) in position R1′ of the parent octapeptide S12 (SAVLQ↓SGF) is replaced by glycine (G). On this position only two mutations are made. In the Jacknife test for P1′G in training set there is only one mutated octapeptide P1′A on the position R1′, no sufficient information on this position. The comparison between experimental and predictive bioactivities of the 21 octapeptides are shown in Figure [5](#fig5){ref-type="fig"}.

![The experimental and predicted bioactivities of octapeptides in training set of 22 octapeptides after 10 iterations. \[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.\]](JCC-28-2043-g004){#fig5}

Peptide‐based vaccines, in which small peptides derived from target proteins (epitopes) are used to provoke an immune reaction, have attracted considerable attention as a potential means both of treating infectious diseases and promoting the destruction of cancerous cells by a patient\'s own immune system.[36](#bib36){ref-type="ref"}, [37](#bib37){ref-type="ref"} With the availability of large sequence databases, computer aided design of peptide‐based vaccines has emerged as a promising approach for screening among billions of possible immune‐active peptides to find those likely to provoke an immune response to a particular cell type. The second example is the affinity prediction for epitope‐peptides with class I MHC (major histocompatibility complex) molecules. Forty samples of 9‐peptides are used in the training set, which are taken form Ref.[38](#bib38){ref-type="ref"}. The 9‐peptide sequences, the experimental bioactivities pIC~50~, and the predicted bioactivities in Jackknife test are shown in Table[4](#tbl4){ref-type="table"}. In the training calculation we get the correlation coefficient *R* = 0.8988 and average residue *Q* = ±0.6246, and in the Jackknife test we get the correlation coefficient *R* = 0.8285 and predictive average residue *Q* = ±0.7949.

###### 

Experimental and Predicted Bioactivities of 40 Epitope‐Peptides.

  Name   Sequence    Exp. pIC~50~ [a](#fn6){ref-type="fn"}   Calc. pIC~5~ [b](#fn7){ref-type="fn"}   Pred. pIC~50~ [c](#fn8){ref-type="fn"}
  ------ ----------- --------------------------------------- --------------------------------------- ----------------------------------------
  P01    WLEPGPVTA   6.082                                   6.341                                   6.582
  P02    ITSQVPFSV   6.196                                   6.495                                   6.568
  P03    FLEPGPVTA   6.898                                   7.163                                   7.465
  P04    ITAQVPFSV   7.020                                   6.799                                   6.726
  P05    YLEPGPVTL   7.058                                   7.364                                   7.498
  P06    YTDQVPFSV   7.066                                   7.498                                   7.758
  P07    YLEPGPVTI   7.187                                   7.375                                   7.443
  P08    YLEPGPVTV   7.342                                   7.453                                   7.461
  P09    YLSPGPVTA   7.383                                   7.305                                   7.287
  P10    IIDQVPFSV   7.398                                   7.667                                   7.707
  P11    ITWQVPFSV   7.463                                   7.362                                   7.348
  P12    ITYQVPFSV   7.480                                   7.302                                   7.234
  P13    ILSQVPFSV   7.699                                   7.797                                   7.815
  P14    IMDQVPFSV   7.719                                   7.717                                   7.717
  P15    YLMPGPVTV   7.932                                   8.056                                   8.074
  P16    WLDQVPFSV   7.939                                   7.574                                   7.285
  P17    YLAPGPVTA   8.032                                   7.608                                   7.526
  P18    YLYPGPVTV   8.051                                   7.998                                   7.975
  P19    YLWPGPVTV   8.125                                   8.058                                   8.090
  P20    ILYQVPFSV   8.310                                   8.603                                   8.648
  P21    ILDQVPFSV   8.481                                   7.827                                   7.713
  P22    YLFPGPVTA   8.495                                   8.131                                   8.069
  P23    YLDQVPFSV   8.638                                   8.799                                   8.892
  P24    ILFQVPFSV   8.699                                   8.623                                   8.605
  P25    ILWQVPFSV   8.770                                   8.663                                   8.649
  P26    WTDQVPFSV   6.145                                   6.273                                   6.381
  P27    YLEPGPVTA   6.668                                   7.567                                   7.748
  P28    ITDQVPFSV   6.947                                   6.526                                   6.643
  P29    ITFQVPFSV   7.179                                   7.321                                   7.344
  P30    FTDQVPFSV   7.212                                   7.094                                   7.028
  P31    ITMQVPFSV   7.398                                   7.360                                   7.357
  P32    YLSPGPVTV   7.642                                   7.191                                   7.124
  P33    YLYPGPVTA   7.772                                   8.111                                   8.147
  P34    YLAPGPVTV   7.818                                   7.495                                   7.466
  P35    ILAQVPFSV   7.939                                   8.100                                   8.119
  P36    ILMQVPFSV   8.125                                   8.661                                   8.749
  P37    YLFPGPVTV   8.237                                   8.017                                   7.981
  P38    YLMPGPVTA   8.367                                   8.169                                   8.135
  P39    YLWPGPVTA   8.495                                   8.171                                   8.112
  P40    FLDQVPFSV   8.658                                   8.395                                   8.191

The experimental bioactivities pIC~50~ are taken from Ref.[38](#bib38){ref-type="ref"}.

Calculated bioactivities pIC~50~ of 9‐peptides in training set.

Predicted bioactivities pIC~50~ of 9‐peptides in Jackknife test.
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Discussion {#sec1-4}
==========

The theoretical model of AABPD is built upon the structure features of peptides with clear physical implications. A merit of the peptide reagent design method developed in this paper is that the binding free energy between peptide reagent P~*i*~ and the target peptide P~0~ is described by the physicochemical parameters of amino acids at every sequence site. It is through eq. [(4)](#eqn4){ref-type="disp-formula"} that has made it possible to not only predict the bioactivities of new peptide reagents, but also describe the physical and chemical features of an amino acid at every sequence position. This is very helpful for designing peptide reagents, peptide analogues, as well as peptide mimetics and modified peptides for drug development. In the traditional QSAR only one set of predictive coefficients {*a* ~*l*~} is used, that is for the physical parameters in linear free energy equation. However, in the AABPD model two sets of predictive coefficients {*a* ~*l*~} and {*b* ~α~} are used for physical parameters and for the position of residues in peptide, respectively. Two least square procedures are performed for {*a* ~*l*~} and {*b* ~α~} alternately and iteratively. In this way the predictive residue *Q* decreases and the correlation coefficient *R* increases step by step. In the first calculation example the first correlation coefficient *R* ^(0)^ = 0.6175 is the results of traditional QSAR method and the converged correlation coefficient *R* ^(10)^ = 0.9705 is the improved result with the AABPD method. Usually after 5--6 iteration steps, the iterative procedure converged smoothly for two sensitive coefficient sets {*a* ~*l*~} and {*b* ~α~}. However, in the case the diversification of peptides is very poor we may get very bad solution, because of the matrix singularity problem. To build a good training set with proper diversification, two criteria have to be satisfied. First, the range of binding affinities in the test set should not exceed the range of affinities in the training set. Second, each amino acid at each position in the test set should also be present at that position in the training set in different peptides.

The iterative double least square (IDLS) technique has been used in more than 10 peptide systems. In all these cases we got converged results. So far we have not observed any unconverged example. In the IDLS technique general inverse matrix method is applied for the least square solution of simultaneous linear equation set. This is a very robust method. Only in the case the diversification of peptide training set is very poor, we may get a very bad solution because of the matrix singularity problem.

Conclusion {#sec1-5}
==========

The linear free energy equation plays an important role in the QSAR study. The physicochemical parameters used in the linear free energy equation should describe the binding free energy from all aspects and include all factors that affect the interaction and recognition between ligand and receptor. Generally speaking, more physical parameters are used in linear free energy equation, better results may be achieved. However, sometimes additional parameters do not work harmonically and may conflict each other. For rational drug design, chemists developed many good parameters for QSAR study. However, the physicochemical parameters of amino acid residues for peptide design are not so ready. For further improvement of AABPD, better linear free energy equations and more optimized physicochemical parameters are needed.
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